Ekaterina Sleptsova

Ms. Ekaterina Sleptsova

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
TRTikhon Sergeevich Redkin
Tikhon Sergeevich Redkin
ESEkaterina Sleptsova
Ekaterina Sleptsova
Victoria D TurubanovaVictoria D Turubanova
Victoria D Turubanova
MSMariia Sаviuk
Mariia Sаviuk
SLSvetlana A. Lermontova
Svetlana A. Lermontova
Dmitri KryskoDmitri Krysko
Dmitri Krysko
Research in the past decade on immunogenic cell death (ICD) has shown that the immunogenicity of dying tumor cells is crucial for effective anticancer therapy. ICD induction leads to the emission of specific damage-associated molecular patterns (DAMPs), which act as danger signals and as adjuvants to activate specific anti-tumor immune responses, leading to the elimination of tumor cells and the formation of long-term immunological memory. ICD can be triggered by many anticancer treatment modalities, including photodynamic therapy (PDT). However, due to the variety of photosensitizers used and the lack of a universally adopted PDT protocol, there is a need to develop novel PDT with a proven ICD capability. In the present study, we characterized the abilities of two photoactive dyes to induce ICD in experimental glioma in vitro and in vivo. One dye was from the tetracyanotetra(aryl)porphyrazine group with 9-phenanthrenyl (pz I), and the other was from the 4-(4-fluorobenzyoxy)phenyl (pz III) group in the aryl frame of the macrocycle. We showed that after the photosensitizers penetrated into murine glioma GL261 cells, they localized predominantly in the Golgi apparatus and partially in the endoplasmic reticulum, providing efficient phototoxic activity against glioma GL261 cells upon light irradiation at a dose of 20 J/cm2 (λex 630 nm; 20 mW/cm2). We demonstrated that pz I-PDT and pz III-PDT can act as efficient ICD inducers when applied to glioma GL261 cells, facilitating the release of two crucial DAMPs (ATP and HMGB1). Moreover, glioma GL261 cells stimulated with pz I-PDT or pz III-PDT provided strong protection against tumor growth in a prophylactic subcutaneous glioma vaccination model. Finally, we showed that dendritic cell (DC) vaccines pulsed with the lysates of glioma GL261 cells pre-treated with pz-I-PDT or pz-III-PDT could act as effective inducers of adaptive anti-tumor immunity in an intracranial orthotopic glioma mouse model.

22 November 2023 in Cancers
Verified
Journal Article
Open access
PDF file
MSMariia Sаviuk
Mariia Sаviuk
ESEkaterina Sleptsova
Ekaterina Sleptsova
TRTikhon Sergeevich Redkin
Tikhon Sergeevich Redkin
Victoria D TurubanovaVictoria D Turubanova
Victoria D Turubanova
Approximately 30% of glioma patients are able to survive beyond one year postdiagnosis. And this short time is often overshadowed by glioma-associated epilepsy. This condition severely impairs the patient’s quality of life and causes great suffering. The genetic, molecular and cellular mechanisms underlying tumour development and epileptogenesis remain incompletely understood, leading to numerous unanswered questions. The various types of gliomas, namely glioblastoma, astrocytoma and oligodendroglioma, demonstrate distinct seizure susceptibility and disease progression patterns. Patterns have been identified in the presence of IDH mutations and epilepsy, with tumour location in cortical regions, particularly the frontal lobe, showing a more frequent association with seizures. Altered expression of TP53, MGMT and VIM is frequently detected in tumour cells from individuals with epilepsy associated with glioma. However, understanding the pathogenesis of these modifications poses a challenge. Moreover, hypoxic effects induced by glioma and associated with the HIF-1a factor may have a significant impact on epileptogenesis, potentially resulting in epileptiform activity within neuronal networks. We additionally hypothesise about how the tumour may affect the functioning of neuronal ion channels and contribute to disruptions in the blood–brain barrier resulting in spontaneous depolarisations.

Verified
Journal Article
Open access
PDF file
ESEkaterina Sleptsova
Ekaterina Sleptsova
OVOlga Vershinina
Olga Vershinina
MIMikhail Ivanchenko
Mikhail Ivanchenko
Victoria D TurubanovaVictoria D Turubanova
Victoria D Turubanova
Gliomas are notoriously difficult to treat owing to their pronounced heterogeneity and highly variable treatment responses. This reality drives the development of precise diagnostic and prognostic methods. This review explores the modern arsenal of bioinformatic tools aimed at refining diagnosis and stratifying glioma patients by different malignancy grades and types. We perform a comparative analysis of software solutions for processing whole-exome sequencing data, analyzing DNA methylation profiles, and interpreting transcriptomic data, highlighting their key advantages and limited applicability in routine clinical practice. Special emphasis is placed on the contribution of bioinformatics to fundamental oncology, as these tools aid in the discovery of new biomarker genes and potential targets for targeted therapy. The ninth section discusses the role of computational models in predicting immunotherapy efficacy. It demonstrates how integrative data analysis—including tumor mutational burden assessment, characterization of the tumor immune microenvironment, and neoantigen identification—can help identify patients who are most likely to respond to immune checkpoint inhibitors and other immunotherapeutic approaches. The obtained data provide compelling justification for including immunotherapy in standard glioma treatment protocols, provided that candidates are accurately selected based on comprehensive bioinformatic analysis. The tools discussed pave the way for transitioning from an empirical to a personalized approach in glioma patient management. However, we also note that this field remains largely in the preclinical research stage and has not yet revolutionized clinical practice. This review is intended for biological scientists and clinicians who find traditional bioinformatic tools difficult to use.

28 March 2024 in Genes & Cells
Verified
Journal Article
Open access
PDF file
ESEkaterina Sleptsova
Ekaterina Sleptsova
TRTikhon Sergeevich Redkin
Tikhon Sergeevich Redkin
MSMariia Sаviuk
Mariia Sаviuk
Victoria D TurubanovaVictoria D Turubanova
Victoria D Turubanova
СОСавюк Мария Олеговна
Савюк Мария Олеговна
The development of cancer immunotherapies provides hope to millions of patients for better clinical outcomes after tumor treatment. Thus, investigating the fundamental mechanisms of antitumor immunity activation is an urgent task. Numerous studies have outlined the effect of immunogenic cell death (ICD) on cancer cells, and this outcome is both sophisticated and simple. Different stimuli can cause ICD; however, photodynamic exposure has been proven to be an effective inducer of programed death on par with radiotherapy. The link between triggering a photodynamic response in cancer cells and triggering ICD has been poorly described in experimental works. The question of which molecular cascades are activated after photodynamic therapy (PDT) irradiation and the way damage-associated molecular patterns (DAMPs) are released is intriguing. Much is known about reactive oxygen species generation and endoplasmic reticulum stress but little about the Golgi apparatus. Photosensitizers of different types can exert different effects, including completely nonimmunogenic ones. This review describes the cascades that link the induction of cell death by photodynamic exposure and the immunogenic pattern of DAMP release. The photosensitizers that have shown potential as ICD inducers and the different pathways of programed death that occur during PDT exposure are also discussed.

8 June 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ESEkaterina Sleptsova
Ekaterina Sleptsova
AKAlina Rinatovna Khuzina
Alina Rinatovna Khuzina
DSDaria A. Sachkova
Daria A. Sachkova
DYDiana V. Yuzhakova
Diana V. Yuzhakova
YSYEVGENIYA Андреевна SANNOVA
YEVGENIYA Андреевна SANNOVA
Victoria D TurubanovaVictoria D Turubanova
Victoria D Turubanova
Background: Photodynamic therapy (PDT) leading to immunogenic cell death (ICD) may serve as a promising basis for the development of antitumor therapeutic strategies. However, the mechanisms of action of photoinduced ICD in primary tumor cultures, including human glioma, remain unexplored. Methods: In the present study, the features of regulated cell death induced by photodynamic therapy using a previously described ICD inducer, porphyrazine III (pz III), were investigated. Cell death was studied in 7 primary cultures of high-grade human gliomas (astrocytomas, oligodendrogliomas, and glioblastomas). Results: Accumulation of porphyrazine III was observed in the endoplasmic reticulum (ER), Golgi apparatus, lysosomes, and mitochondria; however, the distribution of the photosensitizer varied across different cultures. A narrow concentration window of porphyrazine III was established to effectively reach IC85, primarily inducing ferroptosis with contributions from apoptosis and necroptosis accompanied by superoxide anion generation and mitochondrial dysfunction. Conclusions: Given the immunogenic potential of ferroptosis, apoptosis and necroptosis we hypothesize that the induction of PDT using porphyrazine III in glioma will trigger immunogenic cell death.

15 December 2023 in Genes & Cells
Verified
Journal Article
Open access
PDF file
ESEkaterina Sleptsova
Ekaterina Sleptsova
TRT. S. Redkin
T. S. Redkin
MSM. O. Saviuk
M. O. Saviuk
EKE. V. Kondakova
E. V. Kondakova
MVM. V. Vedunova
M. V. Vedunova
DKD. V. Krysko
D. V. Krysko
Investigation of the features of immunogenic cell death caused by photodynamic exposure using a photosensitizer from the tetra(aryl)tetracyanoforfirazines group with 9-phenanthrenyl as a side substituent Исследование особенностей иммуногенной клеточной смерти, опосредованной фотодинамическим воздействием с применением фотосенсибилизатора из группы тетра(арил)тетрацианофорфиразинов с 9-фенантренилом в качестве бокового заместителя